In yesterday’s Wall Street session, Gilead Sciences, Inc. (NASDAQ:GILD) shares traded at $69.58, up 0.04% from the previous session.
GILD stock price is now -6.26% away from the 50-day moving average and -9.74% away from the 200-day moving average. The market capitalization of the company currently stands at $86.76B.
With the price target reduced from $91 to $82, Truist Downgraded its rating from Buy to Hold for Gilead Sciences, Inc. (NASDAQ: GILD). On November 09, 2023, Deutsche Bank recently initiated its ‘Hold’ rating on the stock quoting a target price of $75, while ‘BofA Securities’ rates the stock as ‘Buy’
In other news, GILEAD SCIENCES, INC., 10% Owner bought 485,250 shares of the company’s stock on Apr 02 ’24. The stock was bought for $368,790 at an average price of $0.76. Upon completion of the transaction, the 10% Owner now directly owns 7,345,473 shares in the company, valued at $511.1 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01 ’24, Chief Medical Officer Parsey Merdad sold 2,000 shares of the business’s stock. A total of $145,920 was realized by selling the stock at an average price of $72.96. This leaves the insider owning 96,304 shares of the company worth $6.7 million. A total of 0.10% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc. has had a low of $69.39 and a high of $87.86. As of last week, the company has a debt-to-equity ratio of 1.12, a current ratio of 1.43, and a quick ratio of 1.27. According to the stock market information, the enterprise value for the company is $104.49B, which is based on a 15.45 price-to-earnings ratio, a 3.02 price-to-earnings-growth ratio, and a beta of 0.21. The fifty day moving average price for GILD is $74.02 and a two-hundred day moving average price translates $77.04 for the stock.
The latest earnings results from Gilead Sciences, Inc. (NASDAQ: GILD) was released for Dec, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.72, missing analysts’ expectations of $1.76 by -0.04. This compares to $1.29 EPS in the same period last year. The net profit margin was 20.93% and return on equity was 25.71% for GILD. The company reported revenue of $7.11 billion for the quarter, compared to $7.39 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -3.72 percent. For the current quarter, analysts expect GILD to generate $6.36B in revenue.
